Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313366322> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4313366322 endingPage "66.6" @default.
- W4313366322 startingPage "66.6" @default.
- W4313366322 abstract "Abstract Vaccines are the most successful defense against infectious diseases. Effective vaccines must target induced immune responses to areas of pathogen entry, a primary site being mucosal surfaces. Certain vitamins can directly impact immune cell migration, indicating potential to function as an adjuvant. We previously showed that all-trans retinoic acid (ATRA), the biologically active form of vitamin A, modifies gut-homing receptor expression on effector T cells upon binding to the retinoic acid receptor (RAR), which joins with the retinoid X receptor (RXR) to function. Giving ATRA during vaccination also resulted in enhanced mucosal protection following viral challenge in murine models. While promising, certain factors limit adding ATRA to a vaccine, including its instability and poor solubility. Rexinoids, synthetic ligands for the RXR, could mimic or better ATRA immune effects by enhancing RAR-mediated transcription. Their improved stability and solubility also allows a greater potential for clinical use. Here we explored the ability of different rexinoids to program effector T cell expression of gut-homing receptors CCR9, α4β7, and CD103. Naïve T cells from transgenic mice were activated with peptide and set concentration of each rexinoid. Flow cytometry showed increased expression of gut-homing receptors in the presence of select rexinoids, indicating their ability to act as an ATRA mimic. A cooperative relationship was also seen between other rexinoids and ATRA as co-culturing with suboptimal doses of each showed enhanced receptor expression, suggesting these rexinoids could potentially act with ATRA normally found in serum. Overall, our findings support the prospective use of rexinoids as adjuvants during vaccination." @default.
- W4313366322 created "2023-01-06" @default.
- W4313366322 creator A5024045768 @default.
- W4313366322 creator A5028603389 @default.
- W4313366322 creator A5029458273 @default.
- W4313366322 creator A5034041865 @default.
- W4313366322 creator A5046892542 @default.
- W4313366322 date "2019-05-01" @default.
- W4313366322 modified "2023-09-26" @default.
- W4313366322 title "Novel Vaccine Adjuvants: Exploring the Potential of Rexinoids to Influence Effector T Cell Homing to Mucosal Sites" @default.
- W4313366322 doi "https://doi.org/10.4049/jimmunol.202.supp.66.6" @default.
- W4313366322 hasPublicationYear "2019" @default.
- W4313366322 type Work @default.
- W4313366322 citedByCount "0" @default.
- W4313366322 crossrefType "journal-article" @default.
- W4313366322 hasAuthorship W4313366322A5024045768 @default.
- W4313366322 hasAuthorship W4313366322A5028603389 @default.
- W4313366322 hasAuthorship W4313366322A5029458273 @default.
- W4313366322 hasAuthorship W4313366322A5034041865 @default.
- W4313366322 hasAuthorship W4313366322A5046892542 @default.
- W4313366322 hasConcept C104317684 @default.
- W4313366322 hasConcept C120197328 @default.
- W4313366322 hasConcept C128821507 @default.
- W4313366322 hasConcept C151872237 @default.
- W4313366322 hasConcept C170493617 @default.
- W4313366322 hasConcept C18903297 @default.
- W4313366322 hasConcept C203014093 @default.
- W4313366322 hasConcept C2776090121 @default.
- W4313366322 hasConcept C2777863537 @default.
- W4313366322 hasConcept C2778820923 @default.
- W4313366322 hasConcept C2781121885 @default.
- W4313366322 hasConcept C51785407 @default.
- W4313366322 hasConcept C55493867 @default.
- W4313366322 hasConcept C63932345 @default.
- W4313366322 hasConcept C86339819 @default.
- W4313366322 hasConcept C86803240 @default.
- W4313366322 hasConcept C8891405 @default.
- W4313366322 hasConcept C95444343 @default.
- W4313366322 hasConcept C98274493 @default.
- W4313366322 hasConceptScore W4313366322C104317684 @default.
- W4313366322 hasConceptScore W4313366322C120197328 @default.
- W4313366322 hasConceptScore W4313366322C128821507 @default.
- W4313366322 hasConceptScore W4313366322C151872237 @default.
- W4313366322 hasConceptScore W4313366322C170493617 @default.
- W4313366322 hasConceptScore W4313366322C18903297 @default.
- W4313366322 hasConceptScore W4313366322C203014093 @default.
- W4313366322 hasConceptScore W4313366322C2776090121 @default.
- W4313366322 hasConceptScore W4313366322C2777863537 @default.
- W4313366322 hasConceptScore W4313366322C2778820923 @default.
- W4313366322 hasConceptScore W4313366322C2781121885 @default.
- W4313366322 hasConceptScore W4313366322C51785407 @default.
- W4313366322 hasConceptScore W4313366322C55493867 @default.
- W4313366322 hasConceptScore W4313366322C63932345 @default.
- W4313366322 hasConceptScore W4313366322C86339819 @default.
- W4313366322 hasConceptScore W4313366322C86803240 @default.
- W4313366322 hasConceptScore W4313366322C8891405 @default.
- W4313366322 hasConceptScore W4313366322C95444343 @default.
- W4313366322 hasConceptScore W4313366322C98274493 @default.
- W4313366322 hasIssue "1_Supplement" @default.
- W4313366322 hasLocation W43133663221 @default.
- W4313366322 hasOpenAccess W4313366322 @default.
- W4313366322 hasPrimaryLocation W43133663221 @default.
- W4313366322 hasRelatedWork W1544651817 @default.
- W4313366322 hasRelatedWork W2037973801 @default.
- W4313366322 hasRelatedWork W2039126303 @default.
- W4313366322 hasRelatedWork W2039428739 @default.
- W4313366322 hasRelatedWork W2051277799 @default.
- W4313366322 hasRelatedWork W2058043666 @default.
- W4313366322 hasRelatedWork W2060921414 @default.
- W4313366322 hasRelatedWork W2138096813 @default.
- W4313366322 hasRelatedWork W3017257696 @default.
- W4313366322 hasRelatedWork W4247547560 @default.
- W4313366322 hasVolume "202" @default.
- W4313366322 isParatext "false" @default.
- W4313366322 isRetracted "false" @default.
- W4313366322 workType "article" @default.